Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-13

Study Completion Date

2018-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the addition of acupuncture to standard treatment reduces the level of chemotherapy induced peripheral neuropathy experienced by patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer during or following treatment with neurotoxic chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Acupuncture to Reduce Chemotherapy Induced Peripheral Neuropathy in Gynaecological Cancer Patients

NCT06769061

Gynaecological, Urological or Rectal Cancer Chemotherapy-Induced Peripheral Neuropathy Acupuncture

NOT_YET_RECRUITING NA

Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women

NCT04067544

Chemotherapy-induced Peripheral Neuropathy Breast Cancer Female Gynecologic Cancer

TERMINATED NA

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

NCT03505671

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 +21 more

COMPLETED NA

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932

Breast Cancer Colorectal Cancer

TERMINATED NA

Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors

NCT07120100

Breast Cancer Female Gynecologic Cancer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a significant clinical challenge for patients receiving specific chemotherapy regimen (e.g. taxanes and Bortezomib) and critically, if severe, CIPN can lead to the discontinuation of life prolonging treatment. CIPN poses a major problem for patient care as standard pharmacological treatments for CIPN have been found to be commonly ineffective and are often inadequate due to dosing complexities, delayed analgesic onset and side effects.

A service evaluation of the clinical data secured from using acupuncture to manage CIPN symptoms over a period of 18 months at The Christie National Health Service (NHS) Foundation Trust suggests it has the potential to provide an efficacious management tool to be used in addition to standard medication. This aim of this trial is to formally evaluate a 10 week course of acupuncture in the management of CIPN of grade 2 or above (symptoms experienced have a functional impact, graded in accordance with CTCAE v4.03), in patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer.

This is a randomised, phase II, single-centre, controlled, open label trial . Patients meeting eligibility criteria will be randomised to receive acupuncture plus standard care (treatment arm) or standard care alone (control arm). Patients in both arms of the study will receive standard medication to manage symptoms of CIPN, as determined by a clinician in accordance with local trust policy. In addition to this, patients randomised to the treatment arm will receive 40 minute sessions of acupuncture on a weekly basis for 10 weeks. All patients will be offered acupuncture, to commence off trial at the end of their 10 week study period.

Outcome measures have been focused on assessing the impact of acupuncture on the patients' quality of life, symptom burden of CIPN and quantifying any effect size. There will also be a preliminary health economic evaluation of cost effectiveness. The data will be disseminated in addition to being used to establish whether a larger, multisite trial to confirm efficacy across all diagnostic groups, user acceptability and cost effectiveness is appropriate. This work will facilitate the team validating the study protocol and design as a template for a multicentre study and confirm user acceptability of the approach through additional qualitative data collected through focus group work at the completion of study participation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Multiple Myeloma Gastrointestinal Cancer Gynaecological Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Standard care plus acupuncture

Medication taken to manage the symptom burden of CIPN plus acupuncture

Group Type EXPERIMENTAL

Acupuncture

Intervention Type PROCEDURE

10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.

Medication taken to manage the symptom burden of CIPN

Intervention Type OTHER

Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.

Arm B: Standard care alone

Medication taken to manage the symptom burden of CIPN

Group Type ACTIVE_COMPARATOR

Medication taken to manage the symptom burden of CIPN

Intervention Type OTHER

Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acupuncture

10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.

Intervention Type PROCEDURE

Medication taken to manage the symptom burden of CIPN

Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer who are receiving or who have received neurotoxic chemotherapy treatment for their condition
* The capacity to understand the patient information sheet and the ability to give written informed consent
* Willingness and ability to comply with scheduled visits and study procedures, including the self-report QoL questionnaires and patient diaries
* Age ≥ 18 years; no upper age limit
* CIPN of ≥ Grade II (CTCAE v4.03)
* Platelet count of ≥ 30 x 10\*9/L
* Neutrophil count of ≥ 0.5 x 10\*9/L
* MYMOP2 score of their most troubling CIPN symptom ≥ 3

Exclusion Criteria

* Patients who have previously received acupuncture for neuropathy
* Patients who have received acupuncture for any indication, other than neuropathy, within the previous 6 months
* Women who are pregnant or breast feeding
* Co-morbidity with a bleeding disorder
* Patients with an aversion to needles

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No